MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-gu...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ehdaie, Behfar [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2022 ; number:7 ; pages:910-918 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1470-2045(22)00251-0 |
|---|
| Katalog-ID: |
ELV058259961 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV058259961 | ||
| 003 | DE-627 | ||
| 005 | 20230625004729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(22)00251-0 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica |
| 035 | |a (DE-627)ELV058259961 | ||
| 035 | |a (ELSEVIER)S1470-2045(22)00251-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 35.70 |2 bkl | ||
| 084 | |a 42.12 |2 bkl | ||
| 100 | 1 | |a Ehdaie, Behfar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| 264 | 1 | |c 2022 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. | ||
| 700 | 1 | |a Tempany, Clare M |4 oth | |
| 700 | 1 | |a Holland, Ford |4 oth | |
| 700 | 1 | |a Sjoberg, Daniel D |4 oth | |
| 700 | 1 | |a Kibel, Adam S |4 oth | |
| 700 | 1 | |a Trinh, Quoc-Dien |4 oth | |
| 700 | 1 | |a Durack, Jeremy C |4 oth | |
| 700 | 1 | |a Akin, Oguz |4 oth | |
| 700 | 1 | |a Vickers, Andrew J |4 oth | |
| 700 | 1 | |a Scardino, Peter T |4 oth | |
| 700 | 1 | |a Sperling, Dan |4 oth | |
| 700 | 1 | |a Wong, Jeffrey Y C |4 oth | |
| 700 | 1 | |a Yuh, Bertram |4 oth | |
| 700 | 1 | |a Woodrum, David A |4 oth | |
| 700 | 1 | |a Mynderse, Lance A |4 oth | |
| 700 | 1 | |a Raman, Steven S |4 oth | |
| 700 | 1 | |a Pantuck, Allan J |4 oth | |
| 700 | 1 | |a Schiffman, Marc H |4 oth | |
| 700 | 1 | |a McClure, Timothy D |4 oth | |
| 700 | 1 | |a Sonn, Geoffrey A |4 oth | |
| 700 | 1 | |a Ghanouni, Pejman |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:7 |g pages:910-918 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(22)00251-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 936 | b | k | |a 42.12 |j Biophysik |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 7 |h 910-918 |g 9 | ||
| author_variant |
b e be |
|---|---|
| matchkey_str |
ehdaiebehfartempanyclaremhollandfordsjob:2022----:rgiefcsdlrsudoateayoptetwtitreitrspottc |
| hierarchy_sort_str |
2022 |
| bklnumber |
35.70 42.12 |
| publishDate |
2022 |
| allfields |
10.1016/S1470-2045(22)00251-0 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica (DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Ehdaie, Behfar verfasserin aut MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. Tempany, Clare M oth Holland, Ford oth Sjoberg, Daniel D oth Kibel, Adam S oth Trinh, Quoc-Dien oth Durack, Jeremy C oth Akin, Oguz oth Vickers, Andrew J oth Scardino, Peter T oth Sperling, Dan oth Wong, Jeffrey Y C oth Yuh, Bertram oth Woodrum, David A oth Mynderse, Lance A oth Raman, Steven S oth Pantuck, Allan J oth Schiffman, Marc H oth McClure, Timothy D oth Sonn, Geoffrey A oth Ghanouni, Pejman oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:7 pages:910-918 extent:9 https://doi.org/10.1016/S1470-2045(22)00251-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 7 910-918 9 |
| spelling |
10.1016/S1470-2045(22)00251-0 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica (DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Ehdaie, Behfar verfasserin aut MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. Tempany, Clare M oth Holland, Ford oth Sjoberg, Daniel D oth Kibel, Adam S oth Trinh, Quoc-Dien oth Durack, Jeremy C oth Akin, Oguz oth Vickers, Andrew J oth Scardino, Peter T oth Sperling, Dan oth Wong, Jeffrey Y C oth Yuh, Bertram oth Woodrum, David A oth Mynderse, Lance A oth Raman, Steven S oth Pantuck, Allan J oth Schiffman, Marc H oth McClure, Timothy D oth Sonn, Geoffrey A oth Ghanouni, Pejman oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:7 pages:910-918 extent:9 https://doi.org/10.1016/S1470-2045(22)00251-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 7 910-918 9 |
| allfields_unstemmed |
10.1016/S1470-2045(22)00251-0 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica (DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Ehdaie, Behfar verfasserin aut MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. Tempany, Clare M oth Holland, Ford oth Sjoberg, Daniel D oth Kibel, Adam S oth Trinh, Quoc-Dien oth Durack, Jeremy C oth Akin, Oguz oth Vickers, Andrew J oth Scardino, Peter T oth Sperling, Dan oth Wong, Jeffrey Y C oth Yuh, Bertram oth Woodrum, David A oth Mynderse, Lance A oth Raman, Steven S oth Pantuck, Allan J oth Schiffman, Marc H oth McClure, Timothy D oth Sonn, Geoffrey A oth Ghanouni, Pejman oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:7 pages:910-918 extent:9 https://doi.org/10.1016/S1470-2045(22)00251-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 7 910-918 9 |
| allfieldsGer |
10.1016/S1470-2045(22)00251-0 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica (DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Ehdaie, Behfar verfasserin aut MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. Tempany, Clare M oth Holland, Ford oth Sjoberg, Daniel D oth Kibel, Adam S oth Trinh, Quoc-Dien oth Durack, Jeremy C oth Akin, Oguz oth Vickers, Andrew J oth Scardino, Peter T oth Sperling, Dan oth Wong, Jeffrey Y C oth Yuh, Bertram oth Woodrum, David A oth Mynderse, Lance A oth Raman, Steven S oth Pantuck, Allan J oth Schiffman, Marc H oth McClure, Timothy D oth Sonn, Geoffrey A oth Ghanouni, Pejman oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:7 pages:910-918 extent:9 https://doi.org/10.1016/S1470-2045(22)00251-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 7 910-918 9 |
| allfieldsSound |
10.1016/S1470-2045(22)00251-0 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica (DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 DE-627 ger DE-627 rakwb eng 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Ehdaie, Behfar verfasserin aut MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study 2022 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. Tempany, Clare M oth Holland, Ford oth Sjoberg, Daniel D oth Kibel, Adam S oth Trinh, Quoc-Dien oth Durack, Jeremy C oth Akin, Oguz oth Vickers, Andrew J oth Scardino, Peter T oth Sperling, Dan oth Wong, Jeffrey Y C oth Yuh, Bertram oth Woodrum, David A oth Mynderse, Lance A oth Raman, Steven S oth Pantuck, Allan J oth Schiffman, Marc H oth McClure, Timothy D oth Sonn, Geoffrey A oth Ghanouni, Pejman oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:23 year:2022 number:7 pages:910-918 extent:9 https://doi.org/10.1016/S1470-2045(22)00251-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 23 2022 7 910-918 9 |
| language |
English |
| source |
Enthalten in My London volume:23 year:2022 number:7 pages:910-918 extent:9 |
| sourceStr |
Enthalten in My London volume:23 year:2022 number:7 pages:910-918 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Biochemie: Allgemeines Biophysik |
| institution |
findex.gbv.de |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
My |
| authorswithroles_txt_mv |
Ehdaie, Behfar @@aut@@ Tempany, Clare M @@oth@@ Holland, Ford @@oth@@ Sjoberg, Daniel D @@oth@@ Kibel, Adam S @@oth@@ Trinh, Quoc-Dien @@oth@@ Durack, Jeremy C @@oth@@ Akin, Oguz @@oth@@ Vickers, Andrew J @@oth@@ Scardino, Peter T @@oth@@ Sperling, Dan @@oth@@ Wong, Jeffrey Y C @@oth@@ Yuh, Bertram @@oth@@ Woodrum, David A @@oth@@ Mynderse, Lance A @@oth@@ Raman, Steven S @@oth@@ Pantuck, Allan J @@oth@@ Schiffman, Marc H @@oth@@ McClure, Timothy D @@oth@@ Sonn, Geoffrey A @@oth@@ Ghanouni, Pejman @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003173852 |
| dewey-sort |
3570 |
| id |
ELV058259961 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058259961</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625004729.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(22)00251-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058259961</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(22)00251-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ehdaie, Behfar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tempany, Clare M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Holland, Ford</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sjoberg, Daniel D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kibel, Adam S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trinh, Quoc-Dien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durack, Jeremy C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akin, Oguz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vickers, Andrew J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scardino, Peter T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sperling, Dan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, Jeffrey Y C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuh, Bertram</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Woodrum, David A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mynderse, Lance A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raman, Steven S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pantuck, Allan J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schiffman, Marc H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McClure, Timothy D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sonn, Geoffrey A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghanouni, Pejman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:910-918</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(22)00251-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield><subfield code="h">910-918</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| author |
Ehdaie, Behfar |
| spellingShingle |
Ehdaie, Behfar ddc 570 fid BIODIV bkl 35.70 bkl 42.12 MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| authorStr |
Ehdaie, Behfar |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| topic |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_unstemmed |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| topic_browse |
ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c m t cm cmt f h fh d d s dd dds a s k as ask q d t qdt j c d jc jcd o a oa a j v aj ajv p t s pt pts d s ds j y c w jyc jycw b y by d a w da daw l a m la lam s s r ss ssr a j p aj ajp m h s mh mhs t d m td tdm g a s ga gas p g pg |
| hierarchy_parent_title |
My |
| hierarchy_parent_id |
ELV003173852 |
| dewey-tens |
570 - Life sciences; biology |
| hierarchy_top_title |
My |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003173852 |
| title |
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| ctrlnum |
(DE-627)ELV058259961 (ELSEVIER)S1470-2045(22)00251-0 |
| title_full |
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| author_sort |
Ehdaie, Behfar |
| journal |
My |
| journalStr |
My |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
910 |
| author_browse |
Ehdaie, Behfar |
| container_volume |
23 |
| physical |
9 |
| class |
570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ehdaie, Behfar |
| doi_str_mv |
10.1016/S1470-2045(22)00251-0 |
| dewey-full |
570 |
| title_sort |
mri-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| title_auth |
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| abstract |
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. |
| abstractGer |
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. |
| abstract_unstemmed |
Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| container_issue |
7 |
| title_short |
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study |
| url |
https://doi.org/10.1016/S1470-2045(22)00251-0 |
| remote_bool |
true |
| author2 |
Tempany, Clare M Holland, Ford Sjoberg, Daniel D Kibel, Adam S Trinh, Quoc-Dien Durack, Jeremy C Akin, Oguz Vickers, Andrew J Scardino, Peter T Sperling, Dan Wong, Jeffrey Y C Yuh, Bertram Woodrum, David A Mynderse, Lance A Raman, Steven S Pantuck, Allan J Schiffman, Marc H McClure, Timothy D Sonn, Geoffrey A Ghanouni, Pejman |
| author2Str |
Tempany, Clare M Holland, Ford Sjoberg, Daniel D Kibel, Adam S Trinh, Quoc-Dien Durack, Jeremy C Akin, Oguz Vickers, Andrew J Scardino, Peter T Sperling, Dan Wong, Jeffrey Y C Yuh, Bertram Woodrum, David A Mynderse, Lance A Raman, Steven S Pantuck, Allan J Schiffman, Marc H McClure, Timothy D Sonn, Geoffrey A Ghanouni, Pejman |
| ppnlink |
ELV003173852 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1470-2045(22)00251-0 |
| up_date |
2024-07-06T18:30:37.037Z |
| _version_ |
1803855475023806464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058259961</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625004729.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(22)00251-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001951.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058259961</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(22)00251-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ehdaie, Behfar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Men with grade group 2 or 3 prostate cancer are often considered ineligible for active surveillance; some patients with grade group 2 prostate cancer who are managed with active surveillance will have early disease progression requiring radical therapy. This study aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patients with localised grade group 2 or 3 intermediate-risk prostate cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tempany, Clare M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Holland, Ford</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sjoberg, Daniel D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kibel, Adam S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trinh, Quoc-Dien</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durack, Jeremy C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akin, Oguz</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vickers, Andrew J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scardino, Peter T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sperling, Dan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wong, Jeffrey Y C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yuh, Bertram</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Woodrum, David A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mynderse, Lance A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raman, Steven S</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pantuck, Allan J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schiffman, Marc H</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McClure, Timothy D</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sonn, Geoffrey A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghanouni, Pejman</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:7</subfield><subfield code="g">pages:910-918</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(22)00251-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2022</subfield><subfield code="e">7</subfield><subfield code="h">910-918</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
| score |
7.401045 |